Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NuVasive (NUVA) Boosts Cervical Portfolio With New Buyout

by Zacks Equity Research

NuVasive (NUVA) expands comprehensive portfolio of C360 with the addition of Simplify Disc.

NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines

by Zacks Equity Research

NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.

Earnings Preview: NuVasive (NUVA) Q4 Earnings Expected to Decline

by Zacks Equity Research

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently launched products as well as potential in its U.S. Surgical Support business.

NuVasive (NUVA) Focuses on Cervical Spine Portfolio Expansion

by Zacks Equity Research

The ACP system within NuVasive (NUVA) C360 is targeted to reduce common postoperative complications such as dysphagia, malalignment and adjacent level ossification.

NuVasive (NUVA) Launches C360 Portfolio for Cervical Spine

by Zacks Equity Research

The ACP system within NuVasive's (NUVA) C360 portfolio is targeted to reduce common postoperative complications.

NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.

NuVasive (NUVA) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of 100.00% and 14.09%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

NUVA or SRDX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NUVA vs. SRDX: Which Stock Is the Better Value Option?

NuVasive's (NUVA) MaXcess Retractor Study Results Positive

by Zacks Equity Research

NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.

NuVasive Banks on Product Launches Amid Procedural Volume Loss

by Zacks Equity Research

NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.

Why Is NuVasive (NUVA) Up 1.9% Since Last Earnings Report?

by Zacks Equity Research

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

NuVasive's (NUVA) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.

NuVasive (NUVA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of 18.37% and -0.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Will NuVasive (NUVA) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

NuVasive (NUVA) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NuVasive Launches Reline 3D for Pediatric Patients Globally

by Zacks Equity Research

Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as solid international business.

NuVasive (NUVA) Up 6.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for May 11th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.

NuVasive (NUVA) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of 37.14% and 0.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?